The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma.
 
Takumi Habu
No Relationships to Disclose
 
Hideaki Bando
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Ryosuke Kumanishi
No Relationships to Disclose
 
Takatsugu Ogata
No Relationships to Disclose
 
Takeshi Fujisawa
No Relationships to Disclose
 
Shogo Kumagai
No Relationships to Disclose
 
Hisashi Fujiwara
No Relationships to Disclose
 
Saori Mishima
No Relationships to Disclose
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck Serono; MSD; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Research Funding - CMIC (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Syneos Health (Inst)
 
Masaki Nakamura
Honoraria - AstraZeneca
Consulting or Advisory Role - MSD
 
Hidehiro Hojo
No Relationships to Disclose
 
Yusuke Yoda
No Relationships to Disclose
 
Shohei Koyama
Honoraria - Kaken Pharmaceutical
Consulting or Advisory Role - Kaken Pharmaceutical
Speakers' Bureau - Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb; Ono Pharmaceutical
 
Hiroyoshi Nishikawa
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; MSD K.K; Ono Pharmaceutical
Research Funding - Asahi Kasei; Astellas Pharma; Bayer Yakuhin; Becton Dickinson; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Debiopharm Group; Eisai; Fujifilm; Hitachi; Janssen Research & Development; Kyowa Kirin; MSD K.K.; Oncolys BioPharma; Ono Pharmaceutical; Rakuten Medical; SRL Diagnostics; Sumitomo Dainippon Pharma; Sysmex; Taiho Pharmaceutical; Zenyaku Kogyo
 
Tomonori Yano
No Relationships to Disclose
 
Takeo Fujita
No Relationships to Disclose
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck KGaA; Ono Pharmaceutical; Yakult Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Kei Muro
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen Astellas BioPharma; Astellas Pharma; Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical
 
Takahiro Kinoshita
No Relationships to Disclose
 
Takashi Kojima
Honoraria - Oncolys BioPharma; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; BMS; Merck; MSD
Research Funding - Astellas Amgen BioPharama (Inst); BMS (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Shionogi (Inst)